Structural cells such as airway smooth muscle, myofibroblasts, and fibroblasts play important roles in the pathogenesis of asthma and chronic obstructive pulmonary disease. Although considerable research effort has focused on the effects of steroids on leukocyte function and airway inflammation, few studies have investigated the effects of steroids on structural cell function. There is evidence that structural cells, apart from maintaining the integrity of the bronchial wall, may also participate in airway inflammatory responses. New data suggest that steroids inhibit some but not all proliferative and migratory responses in structural cells. Further, in structural cells the downstream signaling effects altered by glucocorticoids appear to differ from those observed in leukocytes. Therapeutic approaches designed to modulate chemokine and cytokine secretion by structural cells may offer new opportunities to treat diseases characterized by airway obstruction.
Asthma and chronic obstructive pulmonary disease (COPD), chronic diseases affecting millions of people worldwide, are characterized by airway obstruction, airway inflammation, and alterations in structural cell function. The role of structural cells such as airway smooth muscle (ASM), myofibroblasts, and fibroblasts was thought to be maintenance of bronchial wall integrity, but evidence suggests that these cells may be integral components of the inflammatory response as well. This review focuses on the synthetic function of structural cells, which is defined as the ability to secrete immunomodulatory cytokines and chemokines and to express cell surface receptors that are important for cell adhesion and leukocyte activation. Further, it discusses whether the effects of glucocorticoids on structural cell synthetic function could have therapeutic implications.
In diseases characterized by airway obstruction, the most common medications prescribed include antiinflammatory glucocorticoids and bronchodilators such as short-acting (albuterol) or long-acting (formoterol, salmeterol) ␤ 2 -agonists. Glucocorticoids act by binding and activating the cytosolic glucocorticoid receptor. The activated glucocorticoid receptor then undergoes nuclear translocation and interacts in either a cis-or transrepressive manner to inhibit cytokine gene expression (1) . Despite considerable research effort in defining the effects of glucocorticoid receptor activation in regulating leukocyte function, little is known about the role of glucocorticoids in modulating structural cell function. Current evidence suggests that cellular re-sponses to glucocorticoids in structural cells may differ from those observed in leukocytes. Such observations may have important clinical relevance, given the evidence that some patients with asthma or COPD appear to be glucocorticoid insensitive.
CHEMOKINE AND CYTOKINE RELEASE BY ASM CELLS AND FIBROBLASTS
Various cell types that infiltrate the inflamed submucosa present the potential for important cell-cell interactions. Eosinophils, macrophages, and lymphocytes initiate and perpetuate airway inflammation by producing proinflammatory mediators. Evidence also suggests that exposure of ASM to cytokines or growth factors alters contractility and calcium homeostasis (2) and induces smooth muscle cell hypertrophy and hyperplasia (3) .
Studies have revealed that ASM, as well as other structural cells such as myofibroblasts and fibroblasts, secretes a number of cytokines and chemoattractants. Bronchial biopsies of ASM in subjects with mild asthma show constitutive staining for RANTES (the CCL5 chemokine regulated upon activation, normal T cell expressed and secreted) (4) and, in vitro, RANTES secretion in ASM is induced by tumor necrosis factor (TNF)-␣ and interferon-␥ (5-7). Similarly, the CXCL8 chemokine interleukin (IL)-8 is secreted by ASM in response to TNF-␣, IL-1␤, and bradykinin (8) (9) (10) . Other chemokines secreted by structural cells include eotaxin, an eosinophil chemoattractant, and monocyte chemotactic protein (MCP)-1, MCP-2, and MCP-3 (6, 11, 12) (Table 1) (13).
IL-6, a pleiotropic cytokine, induces smooth muscle cell hyperplasia (14) but also modulates B and T cell proliferation and immunoglobulin secretion. IL-6 secretion by ASM cells is inducible by multiple stimuli, including IL-1␤, TNF-␣, transforming growth factor-␤, and sphingosine 1-phosphate, a mediator in asthma (7, 10, (15) (16) (17) . Transgenic expression of IL-6 in the murine lung evokes a peribronchiolar inflammatory infiltrate but promotes airway hyporesponsiveness. These data suggest an intriguing role for IL-6 in controlling local inflammation and regulating airway reactivity (18, 19) , consistent with the known ability of IL-6 to inhibit TNF-␣ and IL-1␤ secretion. ASM cells may also play a role in promoting both the recruitment and survival of eosinophils by secretion of granulocyte-macrophage colonystimulating factor and IL-5 (20) (21) (22) . Additional cytokines that are secreted by human ASM cells include IL-1␤ and other IL-6 family cytokines, such as leukemia inhibitory factor, IL-11, and the thymus-and activation-regulated chemokine (10, 15, 22, 23) .
CORTICOSTEROIDS AND CYTOKINE-INDUCED SYNTHETIC RESPONSES IN STRUCTURAL CELLS
A cornerstone in the management of asthma is the control of airway inflammation. To date, one of the most effective medications for airway inflammation is inhaled corticosteroids. Despite their use for more than 25 years, the precise mechanisms by which steroids improve lung function remain unclear. Because of the therapeutic importance of inhaled corticosteroids in asthma and COPD, investigators have examined whether steroids alter immunomodulatory functions in ASM and fibroblast cells.
TABLE 1. IMMUNOMODULATORY PROTEINS EXPRESSED BY HUMAN AIRWAY SMOOTH MUSCLE CELLS
Definition of abbreviations: CAM ϭ cell adhesion molecule; FcεR ϭ Fc receptor binding IgE; Fc␥R ϭ Fc receptor binding IgG; GM-CSF ϭ granulocyte-macrophage colony-stimulating factor; HLA-DR ϭ human leukocyte antigen; ICAM ϭ intercellular adhesion molecule; IL ϭ interleukin; LFA ϭ leukocyte function-associated antigen; LIF ϭ leukemia inhibitory factor; MCP ϭ monocyte chemotactic protein; NO ϭ nitric oxide; PGE 2 ϭ prostaglandin E 2 ; RANTES ϭ regulated upon activation, normal T cell expressed and secreted; TARC ϭ thymus-and activation-regulated chemokine; VCAM ϭ vascular cell adhesion molecule.
Adapted from Lazaar and Panettieri (13) .
Current evidence suggests that chemokine and cytokine secretion induced by inflammatory mediators is inhibited by dexamethasone in human ASM cells. Cytokine-induced secretion of RANTES (5-7), MCP (6), eotaxin (24) , granulocyte-macrophage colony-stimulating factor (20) , and IL-6 (16) was abrogated with corticosteroids. In most of these studies, corticosteroids and agents that mobilize intracellular cyclic adenosine monophosphate ([cAMP] i ) acted additively to inhibit chemokine and cytokine secretion (7) . Current hypotheses suggest that steroids may directly inhibit gene expression by altering gene promoter activity and/or may abrogate critical signaling events, such as activation of nuclear factor (NF)-B or activator protein (AP)-1, that then modulate gene expression. However, the precise mechanisms by which steroids may regulate synthetic responses in ASM cells remain unknown. (25) . The inhibition of activation of transcription factors, such as NF-B or AP-1, is thought to cause many of the antiinflammatory effects of corticosteroids (25) . Dexamethasone had no effect on TNF-␣-induced or IL-1␤-induced NF-B activation in human ASM cells (26) . Further, cytokine-induced expression of intercellular cell adhesion molecule (ICAM)-1 in ASM cells, which is completely dependent on NF-B activation, was not affected by dexamethasone, whereas IL-1␤-induced cyclooxygenase (COX)-2 expression was abrogated (26) (27) (28) . Collectively, these data support the notion that the antiinflammatory effects of steroids in asthma or COPD may not be due to modulation of cytokine-induced NF-B activation or ICAM-1 expression in human ASM cells. In addition, the cytokine-induced secretion of chemokines, which is exquisitely sensitive to corticosteroids, is probably regulated in part by pathways not dependent on NF-B activation or may be influenced by the context in which the promoter, cofactor, and glucocorticoid receptor interact. Figure 1 summarizes the putative signaling pathways that regulate cytokine-induced ASM synthetic pathways and the pharmacologic agents that modulate these pathways. The inability of steroids to inhibit all cytokineinduced synthetic responses in ASM cells may have important consequences for the local inflammatory responses in the airways and for the development of airway remodeling in bronchi of some patients with chronic severe asthma.
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Glucocorticoids and ␤ 2 -agonists appear to act additively to inhibit structural cell synthetic responses (24, 29) . For example, Pang and Knox demonstrated that glucocorticoids and ␤ 2 -agonists each partially inhibited TNF-␣Ϫinduced eotaxin secretion from ASM cells and had an additive effect in combination (24) . Although Pang and Knox did not examine the underlying transcriptional mechanisms, it is interesting to note that the eotaxin promoter does not contain a cAMP response element (CRE) or glucocorticoid response element (30) . Although the IL-8 promoter does contain a CRE region (31), treatment of ASM cells with ␤ 2 -agonists alone only minimally induced IL-8 secretion, and ␤ 2 -agonists had no effect on IL-8 induction by TNF-␣ (29) . TNF-␣-induced IL-8 secretion was synergistically inhibited by glucocorticoid plus ␤ 2 -agonist combination treatment (29) . ␤ 2 -Agonist treatment did not alter the virtually complete inhibition of TNF-␣-induced RANTES expression that occurred at high glucocorticoid concentrations, but it did render low concentrations of glucocorticoids more efficacious in inhibiting TNF-␣-induced RANTES expression (7) . This might be interpreted as a "glucocorticoid-sparing effect" consistent with that observed in patients with asthma undergoing combination therapy with an inhaled corticosteroid and a ␤ 2 -agonist. Collectively, these studies show that the effect of glucocorticoid plus ␤ 2 -agonist combination therapy on ASM gene expression represents a complex interplay among the transcription factors controlling cytokine gene expression.
INHIBITION OF STRUCTURAL CELL PROLIFERATION AND MIGRATION BY GLUCOCORTICOIDS
Many of the therapies widely used to treat asthma and COPD have been examined for their ability to inhibit ASM cell proliferation in vitro. Although no systematic study of the relative efficacies has been performed, in vitro evidence suggests that antiasthma drugs may, in part, reduce airway remodeling in vivo. Furthermore, these studies provide useful clues for the design of future therapeutic agents to treat airway remodeling in asthma or COPD.
In human ASM cells, dexamethasone or fluticasone propionate arrests ASM cells in the G 1 phase of the cell cycle (32) . Investigators showed that corticosteroids reduced thrombinstimulated increases in cyclin D1 protein and mRNA levels and also attenuated phosphorylation of retinoblastoma protein, via a pathway either downstream of or parallel to the mitogenactivated protein kinase pathway (32) . Evidence suggests that corticosteroids may not be effective in inhibiting ASM cell mitogenesis in response to receptor tyrosine kinase-activating mitogens (33) . In addition, glucocorticoid effects on ASM cell growth also are dependent on ASM-matrix interactions. Evidence suggests that ASM growth on collagen I appears resistant to glucocorticoid inhibition and may relate to integrin-matrix interactions (34) . Collectively, these studies suggest that steroids inhibit some but not all growth factor-induced proliferation of structural cells.
Increased smooth muscle mass is frequently associated with diseases manifested by increased airway or pulmonary vascular resistance (35) (36) (37) . Growth factors, contractile agonists, and inflammatory mediators stimulate abnormal smooth muscle growth by promoting smooth muscle proliferation (38) . Histologic findings suggest that proliferating smooth muscle cells migrate along chemotactic gradients, as evidenced by the invasion of smooth muscle-like cells into the submucosa (39) and the invasion of pulmonary vascular smooth muscle (PVSM) cells into the interstitium (40) . Importantly, agents that stimulate smooth muscle cell proliferation also appear capable of inducing smooth muscle cell migration (41) (42) (43) (44) .
To date, few studies have compared cell migration in both airway and vascular smooth muscle cells. Such studies will be important as researchers target therapeutic approaches to many diseases. Evidence suggests that the combination of a ␤ 2 -agonist and a steroid can be beneficial at both the organ system level (45) and the cellular level (46, 47) , so investigators have examined the effect of glucocorticoids on inhibition of ASM migration as mediated by salmeterol, prostaglandin E 2 (PGE 2 ), and forskolin (an adenylyl cyclase activator). Dexamethasone or fluticasone proprionate, but not salmeterol alone, inhibited ASM cell migration stimulated by platelet-derived growth factor (PDGF), and combined treatment enhanced inhibition. Similarly, overnight pretreatment of ASM cells with fluticasone proprionate augmented the inhibitory effect of PGE 2 and salmeterol on PDGFinduced migration. Also, preincubation of ASM cells with fluticasone proprionate enhanced the inhibitory effect of forskolin on PDGF-induced ASM cell migration. It is unknown whether the primarily additive effect of a glucocorticoid plus a cAMPelevating agent represents contributions of distinct, parallel pathways or rather represents signaling cross-talk/cooperativity, perhaps at the level of cAMP production and activation of protein kinase A. These data demonstrate that pretreatment with fluticasone proprionate or dexamethasone does not alter basal cAMP production or CRE-Luc activity and fails to significantly increase acute cAMP accumulation stimulated by salmeterol. Therefore, under these conditions, glucocorticoid treatment does not enhance ␤ 2 -adrenoceptor responsiveness via mechanisms such as ␤ 2 -adrenoceptor upregulation, as described previously (47) , and the inhibitory effects of glucocorticoids on migration are cAMP/ protein kinase A independent. Pretreatment with fluticasone proprionate or dexamethasone does, however, promote a small but significant increase in salmeterol-stimulated CRE activity, suggesting a small measure of signaling cooperation at the level of gene transcription regulation.
These data highlight cell-specific effects of various mitogens on the migration of human ASM and PVSM cells. In addition, cAMP-generating agents inhibit ASM and PVSM cell migration, and their efficacy seems to be related to their capacity to stimulate cAMP production and protein kinase A activity. Steroids profoundly inhibit PDGF-stimulated migration of ASM and PVSM, and this inhibition is enhanced by salmeterol. Other studies have demonstrated that ␤ 2 -agonists, as well as phosphodiesterase-4 inhibitors, enhance IL-6 secretion and inhibit RANTES secretion in ASM cells (48) .
CONCLUSIONS
Structural cells such as ASM, myofibroblasts, and fibroblasts, which maintain the integrity of the bronchial wall, have now been identified as serving an immunomodulatory role as well. The effects of glucocorticoids on some, but not all, of the inflammatory responses induced by structural cells pose important new research questions. Emerging evidence suggests that the combination of a glucocorticoid with an agent that increases cAMP offers great advantage in inhibiting synthetic responses in structural cells. To date, much of the research gleaned in this area has focused on in vitro cell studies, and future research efforts should be devoted to the correlation of in vitro findings with those derived from in vivo models.
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